Relmada Therapeutics Files 8-K: Board, Officer, and Compensation Updates
Ticker: RLMD · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $476,000, $4,200,00, $2,000,000, $1,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
TL;DR
Relmada's 8-K is in: new execs, new pay, and financials are here.
AI Summary
On January 1, 2025, Relmada Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and certain officers, along with updates to compensatory arrangements. The filing also includes financial statements and exhibits. The company, incorporated in Nevada, operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides crucial updates on the company's leadership and executive compensation, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure of board and officer changes and compensation, not indicating immediate financial distress or significant operational shifts.
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — Registrant
- January 1, 2025 (date) — Earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 2222 Ponce de Leon Blvd. , Floor 3 Coral Gables , FL 33134 (address) — Principal executive offices
FAQ
What specific changes were made to the board of directors or certain officers?
The filing indicates changes in directors and certain officers, but the specific details of these changes are not elaborated upon in the provided text.
What is the nature of the updates to compensatory arrangements?
The filing mentions updates to compensatory arrangements of certain officers, but the specifics of these arrangements are not detailed in the provided text.
What other items are included in this 8-K filing besides director and officer information?
In addition to information on directors and officers, the filing also includes financial statements and exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 1, 2025.
What is Relmada Therapeutics, Inc.'s state of incorporation and principal executive office location?
Relmada Therapeutics, Inc. is incorporated in Nevada and its principal executive offices are located at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134.
Filing Stats: 1,604 words · 6 min read · ~5 pages · Grade level 11.7 · Accepted 2025-01-06 17:29:37
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The NASDAQ
- $476,000 — ny agreed to the following: Salary is $476,000 per year, and he may be entitled to a c
- $4,200,00 — espectively, in the aggregate amount of $4,200,00 for Mr. Traversa, $2,000,000 for each o
- $2,000,000 — e amount of $4,200,00 for Mr. Traversa, $2,000,000 for each of Messrs. Shenouda and Ence a
- $1,500,000 — r each of Messrs. Shenouda and Ence and $1,500,000 for Mr. Kelly. The retention payments w
- $1,050,00 — sum in September 2024 in the amount of $1,050,00 for Mr. Traversa, $500,000 for each of
- $500,000 — e amount of $1,050,00 for Mr. Traversa, $500,000 for each of Messrs. Shenouda and Ence a
- $375,000 — r each of Messrs. Shenouda and Ence and $375,000 for Mr. Kelly. The Retention Compensati
Filing Documents
- ea0226941-8k_relmada.htm (8-K) — 53KB
- ea022694101ex10-1_relmada.htm (EX-10.1) — 63KB
- ea022694101ex10-2_relmada.htm (EX-10.2) — 64KB
- ea022694101ex10-3_relmada.htm (EX-10.3) — 63KB
- ea022694101ex10-4_relmada.htm (EX-10.4) — 63KB
- ea022694101ex10-5_relmada.htm (EX-10.5) — 24KB
- ea022694101ex10-6_relmada.htm (EX-10.6) — 16KB
- ea022694101ex10-7_relmada.htm (EX-10.7) — 25KB
- ea022694101ex10-8_relmada.htm (EX-10.8) — 21KB
- ex10-1_001.jpg (GRAPHIC) — 14KB
- ex10-2_001.jpg (GRAPHIC) — 14KB
- ex10-3_001.jpg (GRAPHIC) — 14KB
- ex10-4_001.jpg (GRAPHIC) — 14KB
- ex10-5_001.jpg (GRAPHIC) — 4KB
- ex10-6_001.jpg (GRAPHIC) — 4KB
- ex10-7_001.jpg (GRAPHIC) — 14KB
- ex10-8_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-001249.txt ( ) — 764KB
- rlmd-20250101.xsd (EX-101.SCH) — 3KB
- rlmd-20250101_lab.xml (EX-101.LAB) — 33KB
- rlmd-20250101_pre.xml (EX-101.PRE) — 22KB
- ea0226941-8k_relmada_htm.xml (XML) — 4KB
01 Financial
Item 9.01 Financial (d) Exhibits. Exhibit No. Description 10.1 Employment Agreement, effective as of January 1, 2025, between Relmada Therapeutics, Inc. and Paul Kelly 10.2 Amended and Restated Employment Agreement, effective as of January 1, 2025, between Relmada Therapeutics, Inc. and Sergio Traversa 10.3 Amended and Restated Employment Agreement, effective as of January 1, 2025, between Relmada Therapeutics, Inc. and Maged Shenouda 10.4 Amended and Restated Employment Agreement, effective as of January 1, 2025, between Relmada Therapeutics, Inc. and Charles Ence 10.5 Retention Compensation Agreement, effective as of August 27, 2024, between Relmada Therapeutics, Inc. and Sergio Traversa 10.6 Retention Compensation Agreement, effective as of August 27, 2024, between Relmada Therapeutics, Inc. and Maged Shenouda 10.7 Retention Compensation Agreement, effective as of August 27, 2024, between Relmada Therapeutics, Inc. and Charles Ence 10.8 Retention Compensation Agreement, effective as of August 27, 2024, between Relmada Therapeutics, Inc. and Paul Kelly 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 6, 2025 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 3